PRN473 Topical

Topical application broadens our portfolio of purpose-designed BTK inhibitors.

PRN473 Topical, a reversible covalent BTK inhibitor, is the company’s third homegrown BTK inhibitor to enter the clinic. Given the abundance of immune cells in skin and their role in immune-mediated diseases, PRN473 Topical is being developed for localized applications. PRN473 Topical is being evaluated in a Phase 1, randomized, double blind, placebo-controlled, single and multiple dose trial to evaluate its safety, tolerability and pharmacokinetics.

Ongoing Clinical Studies

Principia is now a Sanofi company.

As of September 28, 2020, Sanofi and Principia have joined forces to expand and accelerate the potential benefits of therapies for patients with immune-mediated diseases. We will work together to bring these novel therapies to patients faster. Read press release.

Enter Website